Bilimsel Makale Arama | NeuralCipher AI

Kaynak kaydı

Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.

Kobylecki C, Burn DJ, Kass-Iliyya L, Kellett MW, Crossman AR, Silverdale MA.

Parkinsonism Relat Disord · 2014-01-28

DOI: 10.1016/j.parkreldis.2014.01.016PMID: 24521874

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.

Morin N, Jourdain VA, Morissette M, Grégoire L, Di Paolo T.

Neuropharmacology · 2014-01-20

DOI: 10.1016/j.neuropharm.2014.01.014PMID: 24456747

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.

Dézsi L, Vécsei L.

Expert Opin Drug Metab Toxicol · 2014-01-17

DOI: 10.1517/17425255.2014.878702PMID: 24437461

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.

Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I.

J Neurol Neurosurg Psychiatry · 2014-01-16

DOI: 10.1136/jnnp-2013-306787PMID: 24434037

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.

Tereshchenko J, Maddalena A, Bähr M, Kügler S.

Neurobiol Dis · 2014-01-15

DOI: 10.1016/j.nbd.2014.01.009PMID: 24440408

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.

Bavarsad Shahripour R, Harrigan MR, Alexandrov AV.

Brain Behav · 2014-01-13

DOI: 10.1002/brb3.208PMID: 24683506

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Hypomania and mania related to dopamine replacement therapy in Parkinson's disease.

Maier F, Merkl J, Ellereit AL, Lewis CJ, Eggers C, Pedrosa DJ, Kalbe E, Kuhn J, Meyer TD, Zurowski M, Timmermann L.

Parkinsonism Relat Disord · 2014-01-12

DOI: 10.1016/j.parkreldis.2014.01.001PMID: 24467817

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Gene therapy for Parkinson's disease: a step closer?

Stoessl AJ.

Lancet · 2014-01-10

DOI: 10.1016/s0140-6736(13)62108-xPMID: 24412047

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA.

Lancet · 2014-01-10

DOI: 10.1016/s0140-6736(13)61939-xPMID: 24412048

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Initiating levodopa therapy for Parkinson's disease.

Olanow CW, Kieburtz K, Stocchi F.

Mov Disord · 2014-01-09

DOI: 10.1002/mds.25805PMID: 24408661

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.

Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D, Capone JG, Sette E, Golfre-Andreasi N, Tugnoli V, Tola MR, Quatrale R.

J Neural Transm (Vienna) · 2014-01-08

DOI: 10.1007/s00702-013-1153-3PMID: 24398781

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins.

Guerrero-Muñoz MJ, Castillo-Carranza DL, Kayed R.

Biochem Pharmacol · 2014-01-07

DOI: 10.1016/j.bcp.2013.12.023PMID: 24406245

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.

10.361 makale bulundu

Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.

Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.

Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.

Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.

Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.

N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.

Hypomania and mania related to dopamine replacement therapy in Parkinson's disease.

Gene therapy for Parkinson's disease: a step closer?

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Initiating levodopa therapy for Parkinson's disease.

Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.

Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins.

Filtreler